General form for registration of securities under the Securities Act of 1933

Accrued Expenses and Other Current Liabilities (Tables)

v3.25.3
Accrued Expenses and Other Current Liabilities (Tables)
12 Months Ended
Jul. 02, 2025
Sep. 30, 2024
Sonnet BioTherapeutics Holdings, Inc. [Member]    
Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:

 

    June 30, 2025     September 30, 2024  
Compensation and benefits   $ 168,281     $ 149,802  
Research and development     777,846       617,545  
Professional fees     334,821       173,319  
Other     1,958       1,823  
 Accrued expenses and other current liabilities   $ 1,282,906     $ 942,489  

Accrued expenses and other current liabilities consisted of the following:

 

    2024     2023  
    September 30,  
    2024     2023  
Compensation and benefits   $ 149,802     $ 2,091,196  
Research and development     617,545       913,145  
Professional fees     173,319       224,031  
Other     1,823       2,550  
Accrued expenses and other current liabilities   $ 942,489     $ 3,230,922